JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review

[1]  A. Rao,et al.  Dysregulation of the TET family of epigenetic regulators in hematopoietic malignancies. , 2019, Blood.

[2]  B. Stein,et al.  Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know? , 2019, Best practice & research. Clinical haematology.

[3]  L. Holmberg,et al.  Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. , 2018, Leukemia research.

[4]  K. Mills,et al.  Epigenetics in Myeloproliferative Neoplasms , 2017, Journal of cellular and molecular medicine.

[5]  W. Vainchenker,et al.  Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. , 2017, Blood.

[6]  A. Tefferi,et al.  Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors , 2015, Blood Cancer Journal.

[7]  Christian Beisel,et al.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. , 2014, Blood.

[8]  A. Iwama,et al.  TET2 is essential for survival and hematopoietic stem cell homeostasis , 2012, Leukemia.

[9]  E. Pronier,et al.  Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. , 2011, Blood.

[10]  F. Granath,et al.  Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Quesnel,et al.  Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). , 2010, Blood.

[12]  R. Kusec,et al.  Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. , 2010, Blood.

[13]  H. Hsiao,et al.  Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient. , 2008, Leukemia research.

[14]  C. Lam,et al.  Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis , 2006, Annals of Hematology.

[15]  Soon-Siong Teo,et al.  Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. , 2006, Blood.

[16]  P. Campbell,et al.  Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. , 2006, Blood.

[17]  R. Liang,et al.  Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation , 2006, Bone Marrow Transplantation.

[18]  E. Estey,et al.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. , 2005, Blood.